NeoGenomics’ Q4 Revenues Rise 23 Percent on Growing Test Volume | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer genetics testing firm NeoGenomics today reported a 23 percent increase in revenues for the fourth quarter year over year.

For the three months ended Dec. 31, 2013, Ft. Meyers, Fla.-based NeoGenomics posted revenues of $18.3 million, compared to $14.9 million a year ago. Test volume was up 28 percent during the quarter, while average revenue per test slid 4 percent, NeoGenomics said.

The company had a profit of $857,000, or $.02 per share, compared to a net loss of $113,000, or breakeven on a per-share basis, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.